Lv1
30 积分 2020-08-06 加入
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
21天前
已完结
Ⅰ期非小细胞肺癌围术期治疗决策专家共识
2个月前
已完结
抗肿瘤药物首次临床试验起始剂量的一般考虑
2个月前
已完结
Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals
2个月前
已完结
The landscape for radioligand therapies in oncology
3个月前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
3个月前
已完结
Design, Synthesis, and Preclinical Evaluation of 89Zr/177Lu-FAPI-Tz: A Potential Theranostic Pair Targeting Fibroblast Activation Protein
3个月前
已关闭
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
3个月前
已完结
Updated epidemiology of gastrointestinal cancers in East Asia
4个月前
已完结
Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with Locally Advanced or Metastatic Epithelial Tumor: Results from first-in-human phase I/Ib study
4个月前
已完结
皖公网安备34019202002308
